Absence of an effect of t89 on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers

Journal of Clinical Pharmacology

Volumn 54, Issue 2, 2014, Pages 234-239

  Wang, Ping ^a,b   Sun, He ^a,b   Yang, Liu ^a   Li, Ling Yan ^a,b   Hao, Jing ^a   Ruff, Dennis ^c   Guo, Zhi Xin ^a  

^a TIANJIN UNIVERSITY   (China)

^b Tianjin Tasly Group Co Ltd   (China)

^c Icon Development Solutions   (United States)

Author keywords

Interaction; Pharmacodynamics; Pharmacokinetics; T89; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; HERBACEOUS AGENT; T 89; UNCLASSIFIED DRUG; WARFARIN; ANTICOAGULANT AGENT; DANTONIC;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SAFETY; ERYTHEMA; EVENING DOSAGE; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MORNING DOSAGE; OPEN STUDY; PHARMACODYNAMICS; PHARMACOKINETICS; PHLEBITIS; PLASMA CONCENTRATION-TIME CURVE; PROTHROMBIN TIME; SALVIA MILTIORRHIZA; SKIN IRRITATION; SLEEP DISORDER; SLEEP PATTERN; TACHYCARDIA; YOUNG ADULT; ADOLESCENT; BLOOD; HERB DRUG INTERACTION; NORMAL HUMAN;

ADOLESCENT; ADULT; ANTICOAGULANTS; DRUGS, CHINESE HERBAL; FEMALE; HEALTHY VOLUNTEERS; HERB-DRUG INTERACTIONS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PROTHROMBIN TIME; WARFARIN; YOUNG ADULT;

EID: 84895746930     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.209     Document Type: Article

References (20)

1. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. J Am Coll Cardiol. 2003;41:1633-1652.
2. Mirsen TR, Hachinski VC. Transient ischemic attacks and stroke. CMAJ. 1998;138:1099-1105.
3. Management of venous thromboembolism. Lancet. 1988;331:275-277. http://www.sciencedirect.com/science/article/pii/S0140673600028786. Accessed November 11, 2013.
4. Albers GW, Atwood JE, Hirsh J, Sherman DG, Hughes RA, Connolly. Stroke prevention in nonvalvular atrial fibrillation. Ann Intern Med. 1991;115:727-736.
5. Stein PD, Kantrowitz A. Antithrombotic therapy in mechanical and biological prosthetic heart valves and saphenous vein bypass grafts. Chest. 1989;95:107S-117S.
6. Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol. 2005;45:1345-1359.
7. Yu CM, Chan JC, Sanderson JE. Chinese herbs and warfarin potentiation by 'danshen'. J Intern Med. 1997;241:337-339.
8. Izzat MB, Yim AP, El-Zufari MH. A taste of Chinese medicine. Ann Thorac Surg 1998;66:941-942.
9. Chan K, Lo AC, Yeung JH, Woo KS. The effects of danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats. J Pharm Pharmacol. 1995;47:402-406.
10. Izzo AA, Di Carlo G, Borrelli F, Ernst E. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol. 2005;98:1-14.
11. Chu Y, Zhang L, Wang XY, Guo JH, Guo ZX, Ma XH. The effect of Compound Danshen Dripping Pills, a Chinese herb medicine, on the pharmacokinetics and pharmacodynamics of warfarin in rats. J Ethnopharmacol. 2011;137:1457-1461.
12. Chappell J, He J, Knadler MP, Mitchell M, Lee D, Lobo E. Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects. J Clin Pharmacol. 2009;49:1456-1466.
13. Turck D, Su CA, Heinzel G, Busch U, Bluhmki E, Hoffmann J. Lack of interaction between meloxicam and warfarin in healthy volunteers. Eur J Clin Pharmacol. 1997;51(5):421-425.
14. Dingemanse J, Meyerhoff C, Schadrack J., Effect of the catechol-Omethyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin. Br J Clin Pharmacol. 2002;53(5):485-491.
15. Guidance for Industry. In vivo drug metabolism/drug interaction studies-Study design, data analysis, and recommendation for dosing and labeling. Food Drug Adm 1999. http://www.fda.gov/ ohrms/dockets/98fr/981001Gd.pdf. Accessed November 11, 2013.
16. Guidance for Industry. Drug interaction studies, study design, data analysis and implications for dosing and labeling. Food Drug Adm 2006. http://www.fda.gov/OHRMS/DOCKETS/98fr/06d-0344-gdl0001.pdf. Accessed November 11, 2013.
17. Wu WW, Yeung JH. Inhibition of warfarin hydroxylation by major tanshinones of Danshen (Salvia miltiorrhiza) in the rat in vitro and in vivo. Phytomedicine. 2010;17:219-226.
18. Kuo YH, Lin YL, Don MJ, Chen RM, Ueng YF. Induction of cytochrome P450-dependent monooxygenase by extracts of the medicinal herb Salvia miltiorrhiza. J Pharm Pharmacol. 2006;58: 521-527.
19. White CM, Fan C, Chow M. An evaluation of the hemostatic effect of externally applied notoginseng and notoginseng total saponins. J Clin Pharmacol. 2000;40:1150-1153.
20. Yao Y, Wu WY, Liu AH, et al. Interaction of salvianolic acids and notoginsengnosides in inhibition of ADP-induced platelet aggregation. Am J Chin Med. 2008;36:313-328.